Latest News

Oslo, Norway, August 2, 2016 -- Photocure ASA announced today a new systematic review and meta-analysis on the impact of Blue Light Cystoscopy (BLC) with Hexvix® (Hexaminolevulinate) - versus White Light Cystoscopy (WLC) on progression in Non-Muscle Invasive Bladder Cancer (NMIBC).

Oslo, Norway, 6 July 2016: Photocure ASA will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Norway, and is proud to announce Dr. Sia Daneshmand as keynote speaker at the event. Dr. Daneshmand will provide an update on Hexvix/Cysview following the new bladder cancer guidelines from American Urological Association (AUA) and the Society of Urological Oncology (SUO), where enhanced cystoscopy including Blue Light Cystoscopy with Hexvix/ Cysview is recommended.

New Hexvix kit has an improved design providing healthcare professionals with a simplified and easy-to-use product.

New recommendations promise to enable clinicians to provide more individualized patient care.

The video “Blue Light Cystoscopy with Cysview: The USC Experience” presented by Dr. Sia Daneshmand, MD, is one of the 5 top-viewed videos in the VideoUrology™ Journal.

Oslo, Norway, 10 May 2016: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the first quarter 2016.

Oslo, Norway, May 9, 2016 -- Photocure ASA announced today new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview® increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone. The data from the prospective registry, real life, study including 175 patients, was presented at the American Urological Association (AUA) annual meeting in San Diego, CA, May 6-10, 2016.

Oslo, Norway, May 2, 2016: Photocure ASA announced today the American Urological Association (AUA) and the Society of Urological Oncology (SUO) have included enhanced cystoscopy in the 2016 Guidelines for the management of non-muscle invasive bladder cancer (NMIBC). Enhanced cystoscopy including Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® is recommended for increasing the detection and reducing recurrence of NMIBC.

Photocure ASA Oslo, Norway, 26th April 2016: Photocure ASA (OSE: PHO), is pleased to announce publication of a new analysis demonstrating that Blue Light Cystoscopy (BLC) with Hexvix/Cysview significantly prolonged time to disease progression and showed a trend in the reduction of the rate of progression in patients with non-muscle invasive bladder cancer (NMIBC). The data was published online in the April issue of the peer reviewed journal, Bladder Cancer.

Oslo, 6 April 2016: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 28 April 2016 at 17:00 hours (CET).

Oslo, 6 April 2016: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2015.

Introducing Hexvix® Blue Light Flexible Cystoscopy (BLFC) to the routine outpatient follow-up of bladder cancer adds benefits for patients and frees up resources in the hospital with minimal financial impact.

Photocure announces that a new patent for Cevira® has been granted in Europe. Cevira® is one of Photocure’s promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix. The newly granted patent protects the Cevira® drug, its use and its combination with a drug delivery device, such as the Cevira® device, until 2030.

Photocure ASA is pleased to announce presentations by urology researchers on Hexvix® during the European Association of Urology (EAU) annual meeting held in Munich, Germany 11-15 March 2016. The EAU is one of the largest International meetings in urology, showcasing the latest and most relevant knowledge with more than 12,000 urologists and exhibitors from over 100 countries. Hexvix® is a photosensitizing agent taken up selectively by the tumor cells in the bladder that when exposed to blue light during a cystoscopic procedure results in a bright pink fluorescence of the suspicious tissue. Using Hexvix® as an adjunct to standard white light cystoscopy enables the urologist to better detect and remove lesions, leading to a reduced risk of recurrence.

Data from the Visonac® Phase IIb study were presented by Professor Ann-Marie Wennberg at the 15th Annual Euro PDT congress in Barcelona.

Oslo, Norway, 11 February 2016: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the fourth quarter and full year 2015.

Photocure will present its fourth quarter and full year 2015 report on Thursday 11 February 2016 at Hotel Continental, Oslo, Norway.